drugset / Trial / NCT06754930
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with NSCLC.
Timeline
- Start
- 2025-02-18
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-1826 | Unknown | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |
| Background | Ametinib mesylate | Unknown | — | — |
| Background | BP102 | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | SHR-8068 | Monoclonal antibody | — | — |
| Background | SHR-9839 | Unknown | — | — |